Latest Hospitality News

Argenica Therapeutics has completed patient dosing in its Phase 2 trial of ARG-007 for acute ischaemic stroke, with topline data expected in Q3 2025. The company also plans to submit its Investigational New Drug application and Fast Track request to the FDA imminently.

EMVision Medical Devices has commenced the pivotal clinical trial for its emu™ bedside brain scanner aimed at FDA clearance, while advancing its First Responder device through successful aeromedical testing and ethics approvals. The company maintains strong cash reserves of $12.58 million to support ongoing innovation and clinical activities.

OncoSil Medical has reported a remarkable 233% increase in dose sales for Q3 FY25, alongside significant regulatory approvals and strategic expansions that position the company for accelerated growth.

Identitii Limited advances its BNDRY platform with new agreements targeting hospitality and payments sectors, appoints Tim Phillipps as Executive Chair, and reports stable cash flow amid ongoing patent litigation.

ReNerve Limited reported a 39% sales increase in Q3 FY25 alongside compelling clinical validation of its NervAlign® Nerve Cuff and strategic international partnerships, positioning the company for broader market penetration.

Echo IQ Limited marked a pivotal quarter with FDA clearance for EchoSolv AS, strategic US partnerships, and a clear path toward reimbursement and broader commercialisation.

Emyria Limited reports sustained clinical success in its PTSD program, launches a new treatment-resistant depression therapy, and opens a second Empax Centre to meet growing demand. The company is progressing funding discussions with health insurers and government bodies to support expansion.

Medical Developments International reported a robust Q3 FY25 with $8.9 million revenue and $1.7 million operating cashflow, driven by strong Penthrox demand and pricing. New distribution agreements in France and Switzerland position the company for further European expansion.

Murray Cod Australia Ltd reports a remarkable 192% biomass increase, setting the stage for expanded domestic and international sales from May 2025. The company also advances sustainability certifications and strengthens its board to support growth.

Endeavour Group has appointed Jayne Hrdlicka as its new Managing Director and CEO, set to begin in January 2026, signaling a strategic push for growth and transformation under seasoned leadership.

Micro-X Ltd has secured a $5.6 million strategic partnership with Malaysian firm Billion Prima and raised $4 million in capital, marking a pivotal shift towards medical imaging while progressing key security and health technology projects.

Race Oncology has opened a second Australian clinical site for its Phase 1 trial of RC220 combined with doxorubicin in advanced solid tumours, aiming to speed patient enrolment and gather critical safety and efficacy data.